Palvella Therapeutics, Inc. Increase (Decrease) in Derivative Liabilities
Palvella Therapeutics, Inc. (PVLA) reported Increase (Decrease) in Derivative Liabilities of $230.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDerivativeLiabilities · last filed 2026-08-04
- Palvella Therapeutics, Inc. increase (decrease) in derivative liabilities for the quarter ending 2026-06-30 was $114.00K, a 3.39% decline year-over-year.
- Palvella Therapeutics, Inc. increase (decrease) in derivative liabilities for the quarter ending 2026-03-31 was $116.00K, a 54.67% increase year-over-year.
- Palvella Therapeutics, Inc. increase (decrease) in derivative liabilities for the quarter ending 2025-12-31 was $119.00K, a 48.03% decline year-over-year.
- Palvella Therapeutics, Inc. increase (decrease) in derivative liabilities for the quarter ending 2025-09-30 was $82.00K, a 9.33% increase year-over-year.
- Palvella Therapeutics, Inc. increase (decrease) in derivative liabilities for fiscal 2025 was $394.00K, a 37.76% decline from fiscal 2024.
- Palvella Therapeutics, Inc. increase (decrease) in derivative liabilities for fiscal 2024 was $633.00K.
- Palvella Therapeutics, Inc. increase (decrease) in derivative liabilities for fiscal 2023 was -$485.00K.
| Period end | Increase (Decrease) in Derivative Liabilities 3 month | Increase (Decrease) in Derivative Liabilities 6 month | Increase (Decrease) in Derivative Liabilities 9 month | Increase (Decrease) in Derivative Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $114.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $230.00K 10-Q · filed 2026-08-04 | $349.00K derived: sum of 3 quarters · filed 2026-08-04 | $431.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $116.00K 10-Q · filed 2026-05-07 | $235.00K derived: sum of 2 quarters · filed 2026-05-07 | $317.00K derived: sum of 3 quarters · filed 2026-05-07 | $435.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $119.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $201.00K derived: sum of 2 quarters · filed 2026-03-31 | $319.00K derived: sum of 3 quarters · filed 2026-08-04 | $394.00K 10-K · filed 2026-03-31 |
| 2025-09-30 | $82.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $200.00K derived: sum of 2 quarters · filed 2026-08-04 | $275.00K 10-Q · filed 2025-11-12 | $504.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $118.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $193.00K 10-Q · filed 2026-08-04 | $422.00K derived: sum of 3 quarters · filed 2026-08-04 | $497.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $75.00K 10-Q · filed 2026-05-07 | $304.00K derived: sum of 2 quarters · filed 2026-05-07 | $379.00K derived: sum of 3 quarters · filed 2026-05-07 | $650.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $229.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $304.00K derived: sum of 2 quarters · filed 2026-03-31 | $575.00K derived: sum of 3 quarters · filed 2026-03-31 | $633.00K 10-K · filed 2026-03-31 |
| 2024-09-30 | $75.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $346.00K derived: sum of 2 quarters · filed 2025-11-12 | $404.00K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $271.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $329.00K 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | $58.00K 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | -$485.00K 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |